Compare Stocks → New crypto project uncovers 2,050% in 65 days (From InvestorPlace) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NYSE:BKDNASDAQ:CARANASDAQ:KRYSNASDAQ:OYSTNASDAQ:RTRX Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBKDBrookdale Senior Living$6.52+0.9%$6.17$3.33▼$7.05$1.22B1.321.86 million shs1.38 million shsCARACara Therapeutics$0.69-5.5%$0.82$0.50▼$4.67$37.72M0.7667,695 shs363,035 shsKRYSKrystal Biotech$163.97-3.3%$158.80$82.09▼$189.97$4.67B0.85372,180 shs281,100 shsOYSTOyster Point Pharma$11.17$11.15$3.46▼$19.00$299.85M1.31212,171 shs330 shsRTRXTravere Therapeutics$5.80-3.2%$26.56$8.98▼$24.96$296.10M0.67412,277 shs972,749 shs7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBKDBrookdale Senior Living+0.93%-1.95%+2.27%+12.61%+54.50%CARACara Therapeutics-5.72%-14.88%-22.47%+22.12%-83.57%KRYSKrystal Biotech-3.34%-8.88%-1.81%+27.64%+84.01%OYSTOyster Point Pharma0.00%0.00%0.00%0.00%0.00%RTRXTravere Therapeutics-3.17%-13.30%-22.46%-33.64%-72.78%New crypto project uncovers 2,050% in 65 days (Ad)During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.Just click here to sign up and be among the first to get it.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBKDBrookdale Senior Living2.787 of 5 stars2.32.00.04.90.91.70.6CARACara Therapeutics3.9034 of 5 stars3.42.00.04.22.01.71.3KRYSKrystal Biotech3.5561 of 5 stars1.52.00.04.72.63.31.9OYSTOyster Point PharmaN/AN/AN/AN/AN/AN/AN/AN/ARTRXTravere TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBKDBrookdale Senior Living2.50Moderate Buy$7.5015.03% UpsideCARACara Therapeutics2.75Moderate Buy$9.751,313.04% UpsideKRYSKrystal Biotech3.00Buy$164.220.15% UpsideOYSTOyster Point PharmaN/AN/AN/AN/ARTRXTravere TherapeuticsN/AN/AN/AN/ACurrent Analyst RatingsLatest BKD, KRYS, CARA, OYST, and RTRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/16/2024KRYSKrystal BiotechStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$178.00 ➝ $204.004/10/2024CARACara TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.004/9/2024BKDBrookdale Senior LivingRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$9.003/28/2024CARACara TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.003/6/2024CARACara TherapeuticsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$11.00 ➝ $10.003/5/2024CARACara TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.002/27/2024KRYSKrystal BiotechGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$130.00 ➝ $175.002/27/2024KRYSKrystal BiotechCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$160.00 ➝ $195.002/27/2024KRYSKrystal BiotechWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform1/22/2024CARACara TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$6.00 ➝ $5.00(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBKDBrookdale Senior Living$3.01B0.41$0.88 per share7.38$2.15 per share3.03CARACara Therapeutics$20.97M1.80N/AN/A$1.05 per share0.66KRYSKrystal Biotech$50.70M92.20N/AN/A$27.60 per share5.94OYSTOyster Point Pharma$24.54M12.22N/AN/A$3.80 per share2.94RTRXTravere Therapeutics$175.34M1.69N/AN/A$5.15 per share1.13Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBKDBrookdale Senior Living-$189.01M-$0.84N/AN/AN/A-6.27%-44.01%-3.75%5/13/2024 (Estimated)CARACara Therapeutics-$118.51M-$2.18N/AN/AN/A-565.21%-122.10%-89.64%5/20/2024 (Estimated)KRYSKrystal Biotech$10.93M$0.082,049.8844.44N/AN/A-13.31%-12.61%5/13/2024 (Estimated)OYSTOyster Point Pharma-$100.66M-$6.65N/AN/AN/A-901.99%-490.33%-108.29%N/ARTRXTravere Therapeutics-$146.43M-$3.46N/AN/AN/A-49.13%-36.38%-14.90%N/ALatest BKD, KRYS, CARA, OYST, and RTRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/4/202412/31/2023CARACara Therapeutics-$0.57-$0.59-$0.02-$0.59$2.34 million$3.00 million 2/26/202412/31/2023KRYSKrystal Biotech-$0.52$0.30+$0.82$0.30$27.43 million$42.14 million 2/20/2024Q4 2023BKDBrookdale Senior Living-$0.19-$0.40-$0.21-$0.40N/A$754.48 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBKDBrookdale Senior LivingN/AN/AN/AN/AN/ACARACara TherapeuticsN/AN/AN/AN/AN/AKRYSKrystal BiotechN/AN/AN/AN/AN/AOYSTOyster Point PharmaN/AN/AN/AN/AN/ARTRXTravere TherapeuticsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBKDBrookdale Senior Living9.400.800.80CARACara TherapeuticsN/A4.544.43KRYSKrystal BiotechN/A17.7617.55OYSTOyster Point Pharma8.493.353.11RTRXTravere Therapeutics0.667.237.14OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBKDBrookdale Senior LivingN/ACARACara Therapeutics44.66%KRYSKrystal Biotech86.29%OYSTOyster Point Pharma96.70%RTRXTravere TherapeuticsN/AInsider OwnershipCompanyInsider OwnershipBKDBrookdale Senior Living1.50%CARACara Therapeutics4.20%KRYSKrystal Biotech14.10%OYSTOyster Point Pharma17.90%RTRXTravere Therapeutics4.63%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableBKDBrookdale Senior Living25,200189.34 million186.50 millionOptionableCARACara Therapeutics5554.66 million52.36 millionOptionableKRYSKrystal Biotech22928.51 million24.49 millionOptionableOYSTOyster Point Pharma30326.84 million22.04 millionNot OptionableRTRXTravere Therapeutics22151.05 millionN/ANot OptionableBKD, KRYS, CARA, OYST, and RTRX HeadlinesSourceHeadlineCritical Insights From Travere Therapeutics Analyst Ratings: What You Need To Knowmarkets.businessinsider.com - April 17 at 4:04 PMTravere Therapeutics price target lowered by $3 at H.C. Wainwright, here's whyrealmoney.thestreet.com - February 23 at 3:07 PMTravere Therapeutics gains as EU backs kidney disease therapymsn.com - February 23 at 8:37 AMNew Debt & Financing Risk for Travere Therapeutics, Inc. – What’s the Latest?msn.com - February 21 at 8:05 AMTravere Therapeutics price target raised by $4 at Citi, here's whyrealmoney.thestreet.com - February 17 at 7:51 AMTravere Therapeutics: Hold Rating Amidst Filspari’s Steady Performance and Emerging Market Competitionmarkets.businessinsider.com - February 16 at 10:57 AMEarnings Preview For Travere Therapeuticsbenzinga.com - February 14 at 4:00 PMTravere Therapeutics: A Strong Buy on Filspari’s Outperformance and Promising Market Prospectsmarkets.businessinsider.com - January 11 at 7:54 AMOptimistic Outlook for Travere Therapeutics Amid FDA Developments and Strategic Reorganizationmarkets.businessinsider.com - December 7 at 5:53 PMTravere (TVTX) Up on Latest Portfolio Updates & Reorganizationmsn.com - December 6 at 5:04 PMBuy Rating for Travere Therapeutics: Optimism Fueled by Regulatory Prospects and Strategic Reorganizationmarkets.businessinsider.com - December 5 at 8:07 PMTravere Therapeutics upgraded to Buy from Neutral at Citirealmoney.thestreet.com - December 5 at 2:51 PMTravere Shares Rise 8.4%; Co. To Cut Staff, Focus on IgAN, HCU Treatmentsmarketwatch.com - December 4 at 8:55 PMTravere Therapeutics to Present at the 6th Annual Evercore ISI HealthCONx Conferencebenzinga.com - November 21 at 6:25 PMPromising Sales Performance and Growth Prospects Solidify Buy Rating for Travere Therapeuticsmarkets.businessinsider.com - November 8 at 3:32 PMPreview: Travere Therapeutics's Earningsbenzinga.com - November 6 at 2:56 PMTravere Therapeutics Inc Ordinary Shares TVTXmorningstar.com - October 31 at 6:21 PMWedbush Reiterates Travere Therapeutics (TVTX) Outperform Recommendationmsn.com - September 30 at 10:26 AMWhy Former Highflier Travere Therapeutics Just Crashed 41% To A Decade-Lowmsn.com - September 22 at 5:07 PMWhy Shares of Travere Therapeutics Are Slumping Thursdaymsn.com - September 21 at 3:15 PMBack To Back Trial Failures: Analyst Weighs In On Travere Therapeutics' Prospects, Challengesmarkets.businessinsider.com - September 21 at 3:15 PMBank of America Securities Remains a Buy on Travere Therapeutics (TVTX)markets.businessinsider.com - August 31 at 7:43 AMMirum Pharmaceuticals to Buy Bile Acid Product Portfolio from Travere Therapeuticsmarketwatch.com - July 19 at 8:02 PMTVTX ALERT: The Law Offices of Vincent Wong Investigate Travere Therapeutics, Inc. for Potential Violations of Securities Lawsbenzinga.com - June 26 at 8:57 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsBrookdale Senior LivingNYSE:BKDBrookdale Senior Living Inc. owns, manages, and operates senior living communities in the United States. It operates in three segments: Independent Living, Assisted Living and Memory Care, and Continuing Care Retirement Communities (CCRCs). The Independent Living segment owns or leases communities comprising independent and assisted living units in a single community that are primarily designed for middle to upper income seniors. The Assisted Living and Memory Care segment owns or leases communities consisting of freestanding, multi-story communities and freestanding, single-story communities, which offer housing and 24-hour assistance with activities of daily living for the Company's residents. This segment also operates memory care communities for residents with Alzheimer's and other dementias. The CCRCs segment owns or leases communities that provides various living arrangements, such as independent and assisted living, memory care, and skilled nursing; and services to accommodate various levels of physical ability and healthcare needs. It also manages communities on behalf of others. Brookdale Senior Living Inc. was incorporated in 2005 and is headquartered in Brentwood, Tennessee.Cara TherapeuticsNASDAQ:CARACara Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. It also develops Oral difelikefalin, which is in Phase II/III clinical trial to treat chronic pruritus with notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; Vifor Fresenius Medical Care Renal Pharma Ltd. development and commercialization of KORSUVA injection for the treatment of moderate-to-severe pruritus in adult patients undergoing hemodialysis; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.Krystal BiotechNASDAQ:KRYSKrystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.Oyster Point PharmaNASDAQ:OYSTOyster Point Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical therapies to treat ophthalmic diseases in the United States. The company's product candidate is TYRVAYA, a nicotinic acetylcholine receptor agonist for the treatment of signs and symptoms of dry eye disease. It is also developing TYRVAYA that is in Phase II clinical trial for the treatment of for neurotrophic keratopathy. The company was incorporated in 2015 and is headquartered in Princeton, New Jersey.Travere TherapeuticsNASDAQ:RTRXTravere Therapeutics, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. Its products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 8, 2008 and is headquartered in San Diego, CA. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.